Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.
about
New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticlesThe small 11 kDa nonstructural protein of human parvovirus B19 plays a key role in inducing apoptosis during B19 virus infection of primary erythroid progenitor cells.Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP.Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mantle cell lymphoma and small lymphocytic lymphoma.Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotypeB-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progressionHierarchical information clustering by means of topologically embedded graphs.B cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B-cell lymphomaAssessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.The predictive significance of CD20 expression in B-cell lymphomas.De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivityGSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution.Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma.Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls.New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008.Early detection of patients with poor risk diffuse large B-cell lymphoma.Understanding and circumventing resistance to anticancer monoclonal antibodies.Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge.Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma.A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.Anti-Thy-1 Antibody-mediated Complement-dependent Cytotoxicity is Regulated by the Distribution of Antigen, Antibody and Membrane Complement Regulatory Proteins in RatsDifferential gene expression profiling linked to tumor progression of splenic marginal zone lymphoma.An unusual case of Epstein-Barr virus-positive large B-cell lymphoma lacking various B-cell markersOn chip analysis of CNS lymphoma in cerebrospinal fluid.Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphomaReal time analysis of binding between Rituximab (anti-CD20 antibody) and B lymphoma cellsHDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia.Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma.Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls.Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5(+) DLBCL.MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.Distinct Expression and Prognostic Value of MS4A in Gastric Cancer.Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma.
P2860
Q27306995-B1F2A5CD-8985-4FEB-B938-F9C31D4FE944Q33634432-D5DCF2FD-E1E1-488A-966F-1D91E5C322E3Q33710715-14C63AA7-1D39-4D8D-9AF1-18AB6E529817Q33875380-B006933C-8A09-4E2E-A4B0-3D1207519DAFQ34032232-F0ABF7D1-02F1-4317-953C-E033DDAB06DDQ34059352-C48F5F10-9CF1-4C21-8FFA-6ECCEAAA00F1Q34199688-F8657AFF-7532-4DAA-A8CA-32BE26A793C4Q34270046-E926C25B-5867-4DE1-88FE-FE5D4D7CE346Q34543066-EA7316C7-2F23-4B1E-9331-FD119489778FQ34870986-08CA3C6A-FC77-4BB1-8ED9-773730B12EE4Q35051741-BF1CBF3F-E66C-4FB8-9780-D622D48869BCQ35208033-D09A10D0-4643-47AD-97CD-F21D5D9578F3Q35216949-FAD029E9-5416-4861-A84E-68F69CA69BB6Q36161443-9AC44A07-68C1-46DC-8835-8034CD9529A2Q36719078-D5CFB1BA-32ED-4C1B-A095-9BAD6F1611D2Q37212272-259FF45C-9E54-4C55-808A-E24E59240EB9Q37269044-3CFEC72D-3A7F-4A89-AA7F-ECBAD24C4017Q37622271-054F9287-3DE1-4756-97EE-4FBE5A7B6CA4Q37672125-B92ECD92-18B0-4932-A9BC-FABB6B6699C1Q37910910-4315166A-FA84-4014-A76C-90B7090391BFQ38100787-482E4339-9235-4635-9B36-7677FF508097Q39313119-2F55E51A-07A5-41F5-B508-8B91E5F67E9AQ39477266-CD271887-5CD9-4228-8363-24F50B2AAB74Q39688743-2C791367-414F-41BA-A56E-DFD2A58D56F3Q40059586-F613CDDE-4CBA-4428-8F8A-F81E5B30888EQ40351402-65127D15-E8BE-46DB-9842-53E4A22553A7Q40939528-619CAD08-1B46-4A7F-A4D9-AA635DF03F3BQ41645565-FC625F71-E6C1-470D-A73E-E1C89B6A3F90Q42076420-A8FECC3C-05A9-4B25-B732-6FA5F50962D3Q42945834-6B0D4184-9B3F-48C7-8B7B-44127BEBA5A2Q43655408-ECB41587-F315-445F-9056-16756C98E180Q44521795-EE361F56-F22D-4EF6-9C0A-03F8F9C6D4E1Q45372592-E9E25763-AC8F-4067-862F-2EF224736A2AQ46116094-D3FBEC02-5524-40D7-809D-FEDEF6B23AD5Q48117491-17099C36-6BFC-4B14-996B-A0AF2C8F9827Q51286673-D2336E72-DA83-45CD-B121-A83EA759DA12Q52681376-8A72CC37-5879-4CEF-9EC2-91D42D9DE54AQ53507006-6AED7B09-1C99-4E9A-BFED-3C077BED5F7EQ53821747-018C898D-68A8-403C-88C1-0FD7DA18D5D1Q54998752-9749C4A0-F99B-46B8-9FD8-CF20EE10F233
P2860
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Diffuse large B-cell lymphoma: ...... ted with an inferior survival.
@ast
Diffuse large B-cell lymphoma: ...... ted with an inferior survival.
@en
Diffuse large B-cell lymphoma: ...... ted with an inferior survival.
@nl
type
label
Diffuse large B-cell lymphoma: ...... ted with an inferior survival.
@ast
Diffuse large B-cell lymphoma: ...... ted with an inferior survival.
@en
Diffuse large B-cell lymphoma: ...... ted with an inferior survival.
@nl
prefLabel
Diffuse large B-cell lymphoma: ...... ted with an inferior survival.
@ast
Diffuse large B-cell lymphoma: ...... ted with an inferior survival.
@en
Diffuse large B-cell lymphoma: ...... ted with an inferior survival.
@nl
P2093
P2860
P50
P1433
P1476
Diffuse large B-cell lymphoma: ...... ted with an inferior survival.
@en
P2093
Ali Bashashati
Andrew P Weng
Laurie H Sehn
Merrill Boyle
Mukesh Chhanabhai
Nathalie A Johnson
Ryan R Brinkman
Stephen Leach
P2860
P304
P356
10.1182/BLOOD-2008-09-177469
P407
P577
2008-11-24T00:00:00Z